Soligenix, Inc. (NASDAQ:SNGX) on Wednesday announced extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for mild-to-moderate psoriasis.In this extension (Cohort 3) of the exploratory phase of the study, an additional four patients were enrolled and treated with an improved topical gel formulation of synthetic hypericin.The gel formulation was specifically designed to improve ease of application to larger areas of the skin.SGX302 gel therapy was well tolerated by all patients with ...